November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
November 2024 in “Journal of Investigative Dermatology” Certain NK cell changes in blood may indicate alopecia areata progression.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
Changes in skin bacteria may relate to alopecia areata severity.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
September 2024 in “Journal of the American Academy of Dermatology” Microneedling mildly regrows hair in androgenetic alopecia but not in other types.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
July 2024 in “Medical alphabet” The SBN system effectively assesses alopecia areata severity and predicts its course.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
June 2024 in “Zagazig University Medical Journal” Intralesional vitamin D is mildly effective for treating Alopecia Areata.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
June 2024 in “IP Indian journal of clinical and experimental dermatology” PRP therapy effectively treats alopecia areata and atrophic acne scars.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
March 2024 in “Homœopathic Links” Phosphorus homeopathy treatment led to complete hair regrowth in two Alopecia Areata patients.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.